亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

深圳市思科達生物技術有限公司  

專業經營化學標準品,對照品

搜索
新聞中心
  • 暫無新聞
產品分類
  • 暫無分類
聯系方式
  • 聯系人:楊森
  • 電話:0755-89218244
  • 郵件:lq@szskerd.com
  • 傳真:0755-28984072
  • QQ:793285927
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > 吡貝地爾
吡貝地爾
單價 面議對比
詢價 暫無
發貨 廣東深圳市付款后3天內
過期 長期有效
更新 2014-12-02 13:09
 
詳細信息
 吡貝地爾雜質

中文名稱:    吡貝地爾
中文同義詞:    2-[4-(1,3-苯并間二氧雜環戊烯-5-基甲基)哌嗪-1-]嘧啶;吡貝地爾;雙哌嘧啶
英文名稱:    2-[4-(1,3-Benzodioxol-5-ylmethyl)piperazin-1-yl]pyrimidine
英文同義詞:    2-[4-(1,3-benzodioxol-5-ylmethyl)piperazin-1-yl]

pyrimidine;PIRIBEDIL;Piribendyl;PIRIBEDIL(FORR&DONLY0;PIRIBEDIOL;ET-495;EU-4200;Trivastal
CAS:    3605-01-4
分子式:    C16H18N4O2
分子量:    298.34
EINECS:    222-764-6
相關類別:    API;Isotope labelled API
Mol文件:    3605-01-4.mol

規格:10mg/25mg/50mg/100mg

©2025 深圳市思科達生物技術有限公司 版權所有   技術支持:化工網   訪問量:12469  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |